Home > Healthcare > Medical Devices > Diagnostic Devices > Chemiluminescence Immunoassay Market

Chemiluminescence Immunoassay Market Share

Report ID: GMI9477
Published Date: May 2024
Report Format: PDF

Download Free Sample

Chemiluminescence Immunoassay Market Share

The chemiluminescence immunoassay sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.

Chemiluminescence Immunoassay Market Companies

Some of the eminent market participants operating in the chemiluminescence immunoassay industry include:

Abbott Laboratories
Bio-Rad Laboratories, Inc.
Danaher corporation
DiaSorin S.p.A
Eurofins Scientific SE
F. Hoffmann-La Roche Ltd
H.U. Group Holdings, Inc.
Maccura Biotechnology Co., Ltd.
Revvity, Inc.
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Shenzhen New Industries Biomedical Engineering Co., Ltd.
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Tosoh Corporation
Werfen

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Chemiluminescence immunoassay industry size was worth USD 9.8 billion in 2023 and is projected to expand at 7.3% CAGR from 2024 to 2032, due to the rising prevalence of chronic conditions, such as cardiovascular diseases, diabetes, cancer, and infectious diseases.

The consumables product segment in the chemiluminescence immunoassay industry is projected to reach USD 8.2 billion by 2032, owing to the growing trend of decentralized healthcare and point-of-care testing.

The CLEIA technology segment in the chemiluminescence immunoassay industry accounted for USD 5.8 billion in revenue in 2023 and is estimated to witness substantial gains between 2024 and 2032, due to their exceptional sensitivity and specificity.

U.S. chemiluminescence immunoassay industry size is anticipated to record USD 6.6 billion by 2032, led by the ongoing progress in diagnostic technologies, especially in immunoassay methods.